ATOS (Atossa Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $1.76
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics OCF Margin %?

Atossa Therapeutics ATOS -7.89% 26 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Atossa Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Atossa Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-9.58 Mil. Atossa Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Atossa Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Atossa Therapeutics's current OCF Yield % is -191.25%.

The historical rank and industry rank for Atossa Therapeutics's OCF Margin % or its related term are showing as below:


ATOS's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Atossa Therapeutics OCF Margin % Related Terms

Atossa Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics OCF Margin % Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atossa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ATOS
26GF Score
Atossa Therapeutics Inc ATOS
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Atossa Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-29.762/0
= %

Atossa Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-9.581/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Atossa Therapeutics (ATOS) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Atossa Therapeutics and its competitors. According to the industry distribution chart, Atossa Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Atossa Therapeutics' OCF Margin % too high?
Atossa Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Atossa Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' OCF Margin % compare to LTRN and ESLA?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Atossa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Atossa Therapeutics and its competitors. Atossa Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price